abstract: The hypothesis that the termination of sexual receptivity (heat) in female @entity1 results from loss of @entity4 receptors from hypothalamic cell nuclei was tested. First, we attempted to find an optimal dose of @entity2 that would result in a prolonged period of sexual receptivity. Ovariectomized @entity1 were implanted with 10% @entity0 capsules. Forty hours later, each received one of several sized @entity2 capsules before being tested hourly for @entity3 . Surprisingly, none of the @entity2 doses resulted in delayed heat termination. In order to determine whether elevated levels of @entity0 and @entity2 maintain elevated levels of nuclear @entity4 receptors despite the lack of effect on heat duration, animals were treated as described above except that only one size @entity2 capsule (3.0 cm) or an empty capsule was implanted. Despite elevated serum @entity2 concentrations, nuclear @entity4 receptor levels decreased gradually and approached control levels at about the same time as heat termination had occurred in similarly-treated animals. Cytosol @entity4 receptor levels decreased following @entity2 treatment and remained lowered at all times measured. In order to further investigate the relationship between blood @entity2 concentrations and retention of nuclear @entity4 receptors we decreased blood @entity2 concentrations by removing @entity2 capsules 2 h following insertion. Nuclear @entity4 receptor levels declined gradually concurrent with a decline in serum @entity2 levels in animals exposed to @entity2 capsules for only 2 h. In animals exposed to capsules continuously, nuclear @entity4 receptor levels again decreased but at a slightly slower rate. In order to test the effect of @entity2 capsule removal on female sexual behavior, ovariectomized @entity1 were treated as described and tested hourly for @entity3 . Fewer animals in the group exposed to @entity2 capsules for 2 h became sexually receptive as compared to animals continuously-exposed to @entity2 capsules. Of those animals that did respond, heat termination had occurred by the same time that nuclear @entity4 receptor levels had returned to control levels in similarly-treated animals. These experiments support the hypothesis that heat termination results from the loss of @entity4 receptors from hypothalamic cell nuclei. In addition, they demonstrate that circulating @entity2 levels play a role in regulating nuclear @entity4 receptor retention.

title: Loss of hypothalamic nuclear-bound XXXX receptors: factors involved and the relationship to heat termination in female @entity1 .

answer: @entity4


abstract: The hypothesis that the termination of sexual receptivity (heat) in female @entity1 results from loss of @entity4 receptors from hypothalamic cell nuclei was tested. First, we attempted to find an optimal dose of @entity2 that would result in a prolonged period of sexual receptivity. Ovariectomized @entity1 were implanted with 10% @entity0 capsules. Forty hours later, each received one of several sized @entity2 capsules before being tested hourly for @entity3 . Surprisingly, none of the @entity2 doses resulted in delayed heat termination. In order to determine whether elevated levels of @entity0 and @entity2 maintain elevated levels of nuclear @entity4 receptors despite the lack of effect on heat duration, animals were treated as described above except that only one size @entity2 capsule (3.0 cm) or an empty capsule was implanted. Despite elevated serum @entity2 concentrations, nuclear @entity4 receptor levels decreased gradually and approached control levels at about the same time as heat termination had occurred in similarly-treated animals. Cytosol @entity4 receptor levels decreased following @entity2 treatment and remained lowered at all times measured. In order to further investigate the relationship between blood @entity2 concentrations and retention of nuclear @entity4 receptors we decreased blood @entity2 concentrations by removing @entity2 capsules 2 h following insertion. Nuclear @entity4 receptor levels declined gradually concurrent with a decline in serum @entity2 levels in animals exposed to @entity2 capsules for only 2 h. In animals exposed to capsules continuously, nuclear @entity4 receptor levels again decreased but at a slightly slower rate. In order to test the effect of @entity2 capsule removal on female sexual behavior, ovariectomized @entity1 were treated as described and tested hourly for @entity3 . Fewer animals in the group exposed to @entity2 capsules for 2 h became sexually receptive as compared to animals continuously-exposed to @entity2 capsules. Of those animals that did respond, heat termination had occurred by the same time that nuclear @entity4 receptor levels had returned to control levels in similarly-treated animals. These experiments support the hypothesis that heat termination results from the loss of @entity4 receptors from hypothalamic cell nuclei. In addition, they demonstrate that circulating @entity2 levels play a role in regulating nuclear @entity4 receptor retention.

title: Loss of hypothalamic nuclear-bound @entity4 receptors: factors involved and the relationship to heat termination in female XXXX .

answer: @entity1


abstract: Serum @entity5 ( @entity5 ) has been shown to act as an important guardian against cellular damage from oxidized lipids in low-density lipoprotein (LDL), plasma membrane, against toxic agents such as pesticide residues including @entity9 and against bacterial endotoxin. @entity5 associated with circulating high-density lipoprotein (HDL) has the ability to prevent the generation of pro inflammatory oxidized phospholipids by reactive @entity2 species. The activities of the HDL-associated @entity5 and several other anti-inflammatory factors in HDL are in turn negatively regulated by these oxidized lipids. In @entity3 , @entity1 , and @entity0 there appears to be an increase in the formation of these oxidized lipids during the acute phase response. This results in the association of acute phase proteins with HDL and inhibition of the HDL-associated @entity5 that renders HDL pro inflammatory.In populations, low serum HDL- @entity4 is a risk factor for @entity6 and efforts are directed toward therapies to improve the quality and the relative concentrations of LDL and HDL. @entity8 ( @entity8 ) has been shown to reduce @entity6 in laboratory animals. @entity8 , however, is a large protein that is costly and needs to be administered parenterally. Our group has developed @entity8 mimetic peptides that are much smaller than @entity8 (18 @entity7 long vs 243 in @entity8 itself). These HDL mimetic peptides are much more effective in removing the oxidized phospholipids and other oxidized lipids. They improve LDL and HDL composition and function and reduce lesion formation in animal models of @entity6 . Following is a brief description of some of the HDL mimetic peptides that can improve HDL and the effect of the peptide on @entity5 activity.

title: Systemic inflammation, intestine, and XXXX .

answer: @entity5


abstract: OBJECTIVE: To evaluate the effects of body composition as a function of lean mass index (LMI) and body fat (BF) on the correlation between increasing body mass index (BMI; calculated as the weight in kilograms divided by the height in meters squared) and decreasing mortality, which is known as the @entity1 paradox. @entity0 AND METHODS: We retrospectively assessed 47,866 @entity0 with preserved left ventricular ejection fraction (>= 50%). We calculated BF by using the Jackson- @entity2 equation and LMI using (1 - BF)   BMI. The population was divided according to the sex-adjusted BMI classification, sex-adjusted LMI classification, and sex-adjusted BF tertiles. The population was analyzed by using multivariate analysis for total mortality over a mean follow-up duration of 3.1 years by using the National Death Index, adjusting for left ventricular ejection fraction, left ventricular mass index, age, sex, and relative wall thickness. RESULTS: In the entire population, higher BMI was narrowly associated (hazard ratio [HR], 0.99; P<.001) with lower mortality. The higher LMI group was clearly protective (HR, 0.71; P<.001), whereas BF tertile was associated with lower mortality only if no adjustment was made for LMI (HR, 0.87; P<.001 without LMI; HR, 0.97; P=.23 with LMI). In the lean @entity0 , low BMI was clearly associated with higher mortality (HR, 0.92; P<.001) and lower BF tertile was associated with lower mortality only if no adjustment was made for LMI (HR, 0.80; P<.001 without LMI; HR, 1.01; P=.83 with LMI). The underweight @entity0 stratified by BF seemed to have an increased mortality (HR, 1.91; 95% CI, 1.56-2.34) that was independent of LMI. However, in @entity1 @entity0 , both BMI (HR, 1.03; P<.001) and BF (HR, 1.18; P=.003) were associated with higher mortality, even after adjusting for LMI, which remained protective (HR, 0.57; P<.001) independently of BF. CONCLUSION: Body composition could explain the inverse J shape of the mortality curve noted with increasing BMI. Body fat seems to be protective in this cohort only if no adjustment was made for LMI, although being underweight stratified by BF seems to be an independent risk factor. Lean mass index seems to remain protective in @entity1 @entity0 even when BMI is not.

title: Body composition and mortality in a large cohort with preserved ejection fraction: untangling the XXXX paradox.

answer: @entity1


abstract: OBJECTIVE: To determine trends in pharmacotherapy for @entity4 in all @entity0 and in @entity5 ( @entity5 , birth weight 300-1000  g) @entity0 . STUDY DESIGN: We queried the Pediatric Health Information System database for all @entity0  <=28  days with a diagnosis code for @entity4 that were discharged between January 2001 and December 2012. @entity0 were excluded if they had complex @entity2 or cardiac surgery, @entity1 or @entity6 , or had extracorporeal membrane oxygenation. We determined trends in pharmacotherapy for @entity4 in all @entity0 and @entity5 @entity0 , an especially vulnerable group. RESULTS: A total of 8019 @entity4 @entity0 met study criteria. The 2 most prescribed medications were @entity8 (65.3%) and @entity3 (19.9%). For 1487 @entity4 @entity5 @entity0 , the 2 most prescribed medications were @entity8 (83.4%) and @entity7 (33%). During the study period, the use of @entity3 decreased, and @entity7 and vasopressin use increased for all @entity0 and for @entity5 @entity0 . CONCLUSIONS: Treatment of @entity4 varies widely between institutions and individual practitioners, and pharmacotherapy for @entity4 has changed over the past decade. Although @entity8 and @entity3 were the most frequently used agents, their use has declined and the uses of @entity7 and @entity9 have increased.

title: Trends in pharmacotherapy for XXXX .

answer: @entity4


abstract: This study was aimed at investigating the long-term effects of provision of liquid milk replacer (MR) and solid starter diet (SD) during lactation on post-weaning (PW) growth of @entity1 . In experiment 1, 33 cross-bred litters were allotted to four treatments: no supplement (CON), MR   ad libitum, SD   ad libitum and 100   g SD/litter/day from lactation day 4 through weaning at day 21 during late fall. In experiment 2, 40 litters received MR or none in July. PW @entity1 received commercial diets to marketing. In experiment 1, @entity0 ( @entity0 ), pre-weaning average daily gain ( @entity2 ) and mortality (2.4%) were not influenced by creep-feeding MR or SD. @entity2 was greater (P   <   0.05) in the MR group versus CON during days 21-54, but did not differ across the treatments during days 54-162. In experiment 2, @entity2 during lactation and @entity0 were greater in the MR group versus CON, with mortality lower in the former (5.6 vs. 10.3%). However, PW @entity2 to day 175 did not differ between the two groups. Results suggest that creep-feeding MR or SD has no effect on PW growth. However, it remains possible that MR reduces PW mortality during the hot season.

title: Effects of milk replacer and starter diet provided as creep feed for suckling XXXX on pre- and post-weaning growth.

answer: @entity1


abstract: BACKGROUND: Current data from daily practice show that @entity2    analogues, @entity1 and their fixed combination products are used heterogeneously for topical long-term treatment of @entity3 . AIM: To evaluate scientific evidence about topical long-term therapy with @entity5 analogues, @entity1 and their two-compound-products in @entity3 and @entity7 and to develop daily practice recommendations. METHODS: Systematic literature review via PubMed and Embase and informal expert consensus. RESULTS: The search strategy identified 21 relevant clinical trials. Best evidence regarding topical long term treatment was available for the two-compound-formulation containing @entity4 and @entity6 . In a comparative trial in @entity3 the two-compound-formulation showed superior tolerability and cost effectiveness compared to monotherapy. In @entity7 the two-compound-gel was superior compared to @entity4 monotherapy. Standardized and simplified treatment application modes resulted in a better clinical outcome comparing to on-demand therapies. DAILY PRACTICE RECOMMENDATIONS: @entity0 should be proactively involved in the choice of treatment, formulation and mode of application. Besides long-term treatment with the two-compound-formulation other treatment regimens including @entity4 monotherapy can also be considered. Due to a favorable risk-benefit ratio in maintenance trials and due to better cost-effectiveness the application of two-compound-products once or twice a week after initial therapy is recommended.

title: Topical long-term therapy of XXXX with @entity2    analogues, @entity1 and their two compound formulations: position paper on evidence and use in daily practice.

answer: @entity3


abstract: BACKGROUND: Current data from daily practice show that @entity2    analogues, @entity1 and their fixed combination products are used heterogeneously for topical long-term treatment of @entity3 . AIM: To evaluate scientific evidence about topical long-term therapy with @entity5 analogues, @entity1 and their two-compound-products in @entity3 and @entity7 and to develop daily practice recommendations. METHODS: Systematic literature review via PubMed and Embase and informal expert consensus. RESULTS: The search strategy identified 21 relevant clinical trials. Best evidence regarding topical long term treatment was available for the two-compound-formulation containing @entity4 and @entity6 . In a comparative trial in @entity3 the two-compound-formulation showed superior tolerability and cost effectiveness compared to monotherapy. In @entity7 the two-compound-gel was superior compared to @entity4 monotherapy. Standardized and simplified treatment application modes resulted in a better clinical outcome comparing to on-demand therapies. DAILY PRACTICE RECOMMENDATIONS: @entity0 should be proactively involved in the choice of treatment, formulation and mode of application. Besides long-term treatment with the two-compound-formulation other treatment regimens including @entity4 monotherapy can also be considered. Due to a favorable risk-benefit ratio in maintenance trials and due to better cost-effectiveness the application of two-compound-products once or twice a week after initial therapy is recommended.

title: Topical long-term therapy of @entity3 with @entity2    analogues, XXXX and their two compound formulations: position paper on evidence and use in daily practice.

answer: @entity1


abstract: BACKGROUND: Current data from daily practice show that @entity2    analogues, @entity1 and their fixed combination products are used heterogeneously for topical long-term treatment of @entity3 . AIM: To evaluate scientific evidence about topical long-term therapy with @entity5 analogues, @entity1 and their two-compound-products in @entity3 and @entity7 and to develop daily practice recommendations. METHODS: Systematic literature review via PubMed and Embase and informal expert consensus. RESULTS: The search strategy identified 21 relevant clinical trials. Best evidence regarding topical long term treatment was available for the two-compound-formulation containing @entity4 and @entity6 . In a comparative trial in @entity3 the two-compound-formulation showed superior tolerability and cost effectiveness compared to monotherapy. In @entity7 the two-compound-gel was superior compared to @entity4 monotherapy. Standardized and simplified treatment application modes resulted in a better clinical outcome comparing to on-demand therapies. DAILY PRACTICE RECOMMENDATIONS: @entity0 should be proactively involved in the choice of treatment, formulation and mode of application. Besides long-term treatment with the two-compound-formulation other treatment regimens including @entity4 monotherapy can also be considered. Due to a favorable risk-benefit ratio in maintenance trials and due to better cost-effectiveness the application of two-compound-products once or twice a week after initial therapy is recommended.

title: Topical long-term therapy of @entity3 with XXXX    analogues, @entity1 and their two compound formulations: position paper on evidence and use in daily practice.

answer: @entity2


abstract: This study evaluated the @entity4 risk profile of @entity0 with severe @entity2 ( @entity2 ) who received dental treatment under general anesthesia. One hundred and two @entity0 with @entity5 [ @entity5 group, mean age ( @entity1 ); 23.8(9.3)] and 100 healthy @entity0 without @entity5 [NID group, mean age ( @entity1 ); 23.19(3.3)] were included. Medication, disability type, oral hygiene maintenance, and cooperation of the @entity0 were investigated. Dietary habits, plaque index, mutans streptococci counts, @entity3 availability, and salivary buffering were scored and analyzed using the Cariogram. The mean chance of avoiding @entity4 ( @entity1 ) was 28.1(20.4) in the @entity5 group and 54.7(18.4) in the NID group. The @entity5 group had significantly higher numbers of decayed and missing teeth, but fewer filled teeth than the NID group (p < .05). Significant disparities existed in the distributions of all @entity4 -related factors except for mutans streptococci counts between the two groups (p < .05). The low chance to avoid future @entity4 in @entity5 @entity0 was closely associated with insufficient oral hygiene maintenance (p < .05). @entity3 availability was strongly associated with the chance of avoiding @entity4 in the @entity5 group. Dental @entity0 with severe @entity5 exhibited a higher risk of developing @entity4 than normal @entity0 . Among several @entity4 -related factors, insufficient oral hygiene maintenance and low @entity3 availability most contributed to the high risk.

title: Caries risk profile of Korean dental @entity0 with severe XXXX .

answer: @entity2


abstract: This study evaluated the @entity4 risk profile of @entity0 with severe @entity2 ( @entity2 ) who received dental treatment under general anesthesia. One hundred and two @entity0 with @entity5 [ @entity5 group, mean age ( @entity1 ); 23.8(9.3)] and 100 healthy @entity0 without @entity5 [NID group, mean age ( @entity1 ); 23.19(3.3)] were included. Medication, disability type, oral hygiene maintenance, and cooperation of the @entity0 were investigated. Dietary habits, plaque index, mutans streptococci counts, @entity3 availability, and salivary buffering were scored and analyzed using the Cariogram. The mean chance of avoiding @entity4 ( @entity1 ) was 28.1(20.4) in the @entity5 group and 54.7(18.4) in the NID group. The @entity5 group had significantly higher numbers of decayed and missing teeth, but fewer filled teeth than the NID group (p < .05). Significant disparities existed in the distributions of all @entity4 -related factors except for mutans streptococci counts between the two groups (p < .05). The low chance to avoid future @entity4 in @entity5 @entity0 was closely associated with insufficient oral hygiene maintenance (p < .05). @entity3 availability was strongly associated with the chance of avoiding @entity4 in the @entity5 group. Dental @entity0 with severe @entity5 exhibited a higher risk of developing @entity4 than normal @entity0 . Among several @entity4 -related factors, insufficient oral hygiene maintenance and low @entity3 availability most contributed to the high risk.

title: Caries risk profile of Korean dental XXXX with severe @entity2 .

answer: @entity0


abstract: OBJECTIVES: To examine associations between weight change, body composition, risk of @entity2 , and mortality in older adults. DESIGN: Prospective, longitudinal, population-based cohort. SETTING: The Health, Aging, and Body Composition Study. @entity0 : @entity0 (n  =  1,044) and @entity0 (n  =  931) aged 70 to 79. MEASUREMENTS: Weight and lean and fat mass from dual-energy X-ray absorptiometry measured annually over 5  years. Weight was defined as stable (n  =  664, reference), loss (n  =  662), gain (n  =  321), or cycling (gain and loss, n  =  328) using change of 5% from year to year or from Year 1 to 6. Mobility disability (two consecutive reports of difficulty walking one-quarter mile or climbing 10 steps) and mortality were determined for 8  years after the weight change period. Associations were analyzed using Cox proportional hazards regression adjusted for covariates. RESULTS: During follow-up, 313 @entity0 and 375 @entity0 developed @entity2 , and 322 @entity0 and 378 @entity0 died. There was no risk of @entity2 or mortality with @entity3 . Weight loss (hazard ratio (HR)  =  1.88, 95% confidence interval (CI)  =  1.40-2.53) and weight cycling (HR  =  1.59, 95% CI  =  1.11-2.29) were associated with @entity2 in @entity0 , and @entity1 was associated with @entity2 in @entity0 (HR  =  1.30, 95% CI  =  1.01-1.69). Weight loss and weight cycling were associated with mortality risk in @entity0 ( @entity1 : HR  =  1.47, 95% CI  =  1.07-2.01; weight cycling: HR  =  1.62, 95% CI  =  1.15-2.30) and in @entity0 ( @entity1 : HR  =  1.41, 95% CI  =  1.09-1.83; weight cycling: HR  =  1.50, 95% CI  =  1.08-2.08). Adjustment for lean and fat mass and change in lean and fat mass from Year 1 to 6 attenuated the relationships between @entity1 and @entity2 in @entity0 and between @entity1 and mortality in @entity0 and @entity0 . CONCLUSION: Weight cycling and @entity1 predict impending @entity2 and mortality in old age, underscoring the prognostic importance of weight history.

title: Weight change, body composition, and risk of XXXX and mortality in older adults: a population-based cohort study.

answer: @entity2


abstract: The pharmacokinetics of high-dose @entity5 was studied in 18 @entity0 with @entity1 . Nine male and nine female @entity0 with a mean age of 14.7 years (range 3 to 29 years) participated in the study. They received @entity4 450 mg/kg/day (as the @entity3 ) in six divided doses. During a steady-state dosing interval, a dose of @entity4 was coadministered with a 10-mg/kg dose of @entity2 as a 30-minute infusion. Serum concentrations of @entity4 and @entity2 were determined by high-pressure liquid chromatography assay. The data were analyzed using model-independent methods. The mean elimination rate constant for @entity4 was 0.64 +/- 0.22 hr-1 and the mean serum half-life was 1.22 +/- 0.39 hr. Total clearance of @entity4 , calculated by noncompartmental analysis, was 77.2 +/- 26.4 mL/min/sq m. Glomerular filtration rate, as estimated by measuring @entity2 clearance, was 79.6 +/- 21.9 mL/min/sq m. The total clearance of @entity4 correlated with @entity2 clearance. @entity0 with @entity1 appear to eliminate @entity4 more rapidly than healthy individuals. This rapid elimination warrants the use of high doses to maintain high serum concentrations.

title: Pharmacokinetics of high-dose XXXX in @entity0 with @entity1 .

answer: @entity5


abstract: The pharmacokinetics of high-dose @entity5 was studied in 18 @entity0 with @entity1 . Nine male and nine female @entity0 with a mean age of 14.7 years (range 3 to 29 years) participated in the study. They received @entity4 450 mg/kg/day (as the @entity3 ) in six divided doses. During a steady-state dosing interval, a dose of @entity4 was coadministered with a 10-mg/kg dose of @entity2 as a 30-minute infusion. Serum concentrations of @entity4 and @entity2 were determined by high-pressure liquid chromatography assay. The data were analyzed using model-independent methods. The mean elimination rate constant for @entity4 was 0.64 +/- 0.22 hr-1 and the mean serum half-life was 1.22 +/- 0.39 hr. Total clearance of @entity4 , calculated by noncompartmental analysis, was 77.2 +/- 26.4 mL/min/sq m. Glomerular filtration rate, as estimated by measuring @entity2 clearance, was 79.6 +/- 21.9 mL/min/sq m. The total clearance of @entity4 correlated with @entity2 clearance. @entity0 with @entity1 appear to eliminate @entity4 more rapidly than healthy individuals. This rapid elimination warrants the use of high doses to maintain high serum concentrations.

title: Pharmacokinetics of high-dose @entity5 in @entity0 with XXXX .

answer: @entity1


abstract: The pharmacokinetics of high-dose @entity5 was studied in 18 @entity0 with @entity1 . Nine male and nine female @entity0 with a mean age of 14.7 years (range 3 to 29 years) participated in the study. They received @entity4 450 mg/kg/day (as the @entity3 ) in six divided doses. During a steady-state dosing interval, a dose of @entity4 was coadministered with a 10-mg/kg dose of @entity2 as a 30-minute infusion. Serum concentrations of @entity4 and @entity2 were determined by high-pressure liquid chromatography assay. The data were analyzed using model-independent methods. The mean elimination rate constant for @entity4 was 0.64 +/- 0.22 hr-1 and the mean serum half-life was 1.22 +/- 0.39 hr. Total clearance of @entity4 , calculated by noncompartmental analysis, was 77.2 +/- 26.4 mL/min/sq m. Glomerular filtration rate, as estimated by measuring @entity2 clearance, was 79.6 +/- 21.9 mL/min/sq m. The total clearance of @entity4 correlated with @entity2 clearance. @entity0 with @entity1 appear to eliminate @entity4 more rapidly than healthy individuals. This rapid elimination warrants the use of high doses to maintain high serum concentrations.

title: Pharmacokinetics of high-dose @entity5 in XXXX with @entity1 .

answer: @entity0


abstract: OBJECTIVE: To evaluate the anti-nociceptive and sedative effects of slow intravenous (IV) injection of @entity2 , @entity3 , or a combination of both drugs in ponies. STUDY DESIGN: Within-subject blinded. ANIMALS: Twenty ponies (seven male, 13 female, weighing mean      SD 268.0      128  kg). METHODS: On separate occasions, each pony received one of the following three treatments IV; @entity3 50   g  kg(-) (R) @entity2 3  mg  kg(-1) given over 15  minutes (T) or @entity2 3  mg  kg(-1) followed by @entity3 50   g  kg(-1) ( @entity0 ). Physiologic parameters and caecal borborygmi (CB) were measured and sedation and response to electrical stimulation of the coronary band assessed before and up to 120  minutes following drugs administration. Results were analyzed using the Friedman's test and 2 way anova as relevant. RESULTS: When compared to baseline, @entity1 ( @entity1 , beats minute(-1) ) and respiratory rates (fR , breaths minute(-1) ) increased with treatment T (highest mean      SD, @entity1 43      1; fR 33      2) and decreased with R (lowest @entity1 29      1 and fR 10      4) and @entity0 (lowest @entity1 32      1 and fR 9      3). There were no changes in other measured physiological variables. The height of head from the ground was lower following treatments R and TR than T. There was slight ataxia with all three treatments. No excitatory behavioural effects were observed. The response to electrical stimulation was reduced for a prolonged period relative to baseline following all three treatments, the effect being significantly greatest with treatment @entity0 . CONCLUSION: @entity2 combined with @entity3 at the stated doses proved an effective sedative and anti-nociceptive combination in ponies, with no unacceptable behavioural or physiologic side effects. CLINICAL RELEVANCE: Slow controlled administration of @entity2 should reduce the occurrence of adverse behavioural side effects.

title: Anti-nociceptive and sedative effects of XXXX , @entity2 and their combination administered intravenously slowly in ponies.

answer: @entity3


abstract: OBJECTIVE: To evaluate the anti-nociceptive and sedative effects of slow intravenous (IV) injection of @entity2 , @entity3 , or a combination of both drugs in ponies. STUDY DESIGN: Within-subject blinded. ANIMALS: Twenty ponies (seven male, 13 female, weighing mean      SD 268.0      128  kg). METHODS: On separate occasions, each pony received one of the following three treatments IV; @entity3 50   g  kg(-) (R) @entity2 3  mg  kg(-1) given over 15  minutes (T) or @entity2 3  mg  kg(-1) followed by @entity3 50   g  kg(-1) ( @entity0 ). Physiologic parameters and caecal borborygmi (CB) were measured and sedation and response to electrical stimulation of the coronary band assessed before and up to 120  minutes following drugs administration. Results were analyzed using the Friedman's test and 2 way anova as relevant. RESULTS: When compared to baseline, @entity1 ( @entity1 , beats minute(-1) ) and respiratory rates (fR , breaths minute(-1) ) increased with treatment T (highest mean      SD, @entity1 43      1; fR 33      2) and decreased with R (lowest @entity1 29      1 and fR 10      4) and @entity0 (lowest @entity1 32      1 and fR 9      3). There were no changes in other measured physiological variables. The height of head from the ground was lower following treatments R and TR than T. There was slight ataxia with all three treatments. No excitatory behavioural effects were observed. The response to electrical stimulation was reduced for a prolonged period relative to baseline following all three treatments, the effect being significantly greatest with treatment @entity0 . CONCLUSION: @entity2 combined with @entity3 at the stated doses proved an effective sedative and anti-nociceptive combination in ponies, with no unacceptable behavioural or physiologic side effects. CLINICAL RELEVANCE: Slow controlled administration of @entity2 should reduce the occurrence of adverse behavioural side effects.

title: Anti-nociceptive and sedative effects of @entity3 , XXXX and their combination administered intravenously slowly in ponies.

answer: @entity2


abstract: STUDY DESIGN: cized, single-blind, controlled trial. OBJECTIVE: To investigate the efficacy of the Arthrokinematic approach (AKA)-Hakata (H) method for @entity3 . SUMMARY OF BACKGROUND DATA: The AKA-H method is used to manually treat @entity2 . METHODS: One hundred eighty-six @entity0 with chronic nonspecific @entity3 randomly received either the AKA-H method (AKA-H group) or the sham technique (S group) monthly for 6 months. Data were collected at baseline and once a month. Outcome measures were @entity1 intensity (visual analogue scale [VAS]) and quality of life (the Roland-Morris Disability Questionnaire [RDQ] and Short Form SF-36 questionnaire [SF-36]). RESULTS: At baseline, the VAS, RDQ, and SF-36 scores showed similar levels between the groups. After 6 months, the AKA-H group had more improvement in the VAS (42.8% improvement) and RDQ score (31.1% improvement) than the sham group (VAS: 10.4% improvement; RDQ: 9.8% improvement; both, P < 0.001). The respective scores for the SF-36 subscales (physical functioning, role physical, bodily @entity1 , social functioning, general health perception, role emotional, and mental health) were also significantly more improved in the AKA-H group than in the sham group (all, P < 0.001). The scores for the physical, psychological, and social aspects of the SF-36 subscales showed similar improvement in the AKA-H group. CONCLUSION: The AKA-H method can be effective in managing @entity3 . TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR) UMIN000006250.

title: A Randomized, Single-Blind, Placebo-Controlled Study on the Efficacy of the Arthrokinematic Approach-Hakata Method in @entity0 with Chronic Nonspecific Low Back XXXX .

answer: @entity1


abstract: STUDY DESIGN: cized, single-blind, controlled trial. OBJECTIVE: To investigate the efficacy of the Arthrokinematic approach (AKA)-Hakata (H) method for @entity3 . SUMMARY OF BACKGROUND DATA: The AKA-H method is used to manually treat @entity2 . METHODS: One hundred eighty-six @entity0 with chronic nonspecific @entity3 randomly received either the AKA-H method (AKA-H group) or the sham technique (S group) monthly for 6 months. Data were collected at baseline and once a month. Outcome measures were @entity1 intensity (visual analogue scale [VAS]) and quality of life (the Roland-Morris Disability Questionnaire [RDQ] and Short Form SF-36 questionnaire [SF-36]). RESULTS: At baseline, the VAS, RDQ, and SF-36 scores showed similar levels between the groups. After 6 months, the AKA-H group had more improvement in the VAS (42.8% improvement) and RDQ score (31.1% improvement) than the sham group (VAS: 10.4% improvement; RDQ: 9.8% improvement; both, P < 0.001). The respective scores for the SF-36 subscales (physical functioning, role physical, bodily @entity1 , social functioning, general health perception, role emotional, and mental health) were also significantly more improved in the AKA-H group than in the sham group (all, P < 0.001). The scores for the physical, psychological, and social aspects of the SF-36 subscales showed similar improvement in the AKA-H group. CONCLUSION: The AKA-H method can be effective in managing @entity3 . TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR) UMIN000006250.

title: A Randomized, Single-Blind, Placebo-Controlled Study on the Efficacy of the Arthrokinematic Approach-Hakata Method in XXXX with Chronic Nonspecific Low Back @entity1 .

answer: @entity0


abstract: Numerous bacteria in and on its external parts protect the @entity0 body from harmful threats. This study aimed to investigate the potential beneficial effects of the vaginal ecosystem microbiota. A type of bacteria was isolated from vaginal secretions of adolescent and young adult @entity0 , cultured on an appropriate specific culture medium, and then molecularly identified through 16S rDNA gene sequencing. Results of 16S rDNA sequencing revealed that the isolate belongs to the @entity2 species. The isolated strain exhibited probiotic properties such as low pH and high @entity3 concentration tolerance, antibiotic susceptibility and antimicrobial activity against some pathogenic bacteria. The anticancer effects of the strain on @entity0 @entity1 cell lines (cervical, HeLa; gastric, AGS; colon, HT-29; breast, MCF-7) and on a @entity0 normal cell line ( @entity0 umbilical vein endothelial cells [HUVEC]) were investigated. Toxic side effects were assessed by studying apoptosis in the treated cells. The strain exhibited desirable probiotic properties and remarkable anticancer activity against the tested @entity0 @entity1 cell lines (P    <=   0.05) with no significant cytotoxic effects on HUVEC normal cells (P    <=   0.05). Overall, the isolated strain showed favorable potential as a bioactive therapeutic agent. Therefore, this strain should be subjected to the other required tests to prove its suitability for clinical therapeutic application.

title: Assessment of probiotic potential and anticancer activity of newly isolated vaginal bacterium XXXX 5BL.

answer: @entity2


abstract: BACKGROUND AND OBJECTIVE: Both gingival tissue destruction and regeneration are associated with @entity3 , although the former overwhelms the latter. Studies have shown that @entity2 ( @entity2 ), a growth factor largely involved in tissue regeneration and remodeling, is upregulated in @entity3 . However, the gingival expression of connective tissue growth factor ( @entity4 or @entity4 ), a @entity2 -upregulated gene, in @entity0 with @entity1 remains undetermined. Although both @entity4 / @entity4 and @entity2 increase the production of extracellular matrix, they have many different biological functions. Therefore, it is important to delineate the impact of @entity1 on gingival @entity4 / @entity4 expression. MATERIAL AND METHODS: Periodontal tissue specimens were collected from seven individuals without @entity1 (group 1) and from 14 with @entity1 (group 2). The expression of @entity4 and @entity2 mRNAs were quantified using real-time PCR. RESULTS: Analysis using the nonparametric Mann-Whitney U-test showed that the levels of expression of both @entity4 / @entity4 and @entity2 mRNAs were significantly increased in individuals with @entity1 compared with individuals without @entity1 . Furthermore, analysis using a nonparametric correlation (Spearman r) test showed a positive correlation between @entity2 and @entity4 / @entity4 mRNAs. CONCLUSION: The gingival expression levels of @entity4 / @entity4 and @entity2 mRNAs in individuals with @entity1 are upregulated and correlated.

title: Increased and correlated expression of connective tissue growth factor and @entity2 in surgically removed periodontal tissues with XXXX .

answer: @entity3


abstract: BACKGROUND AND OBJECTIVE: Both gingival tissue destruction and regeneration are associated with @entity3 , although the former overwhelms the latter. Studies have shown that @entity2 ( @entity2 ), a growth factor largely involved in tissue regeneration and remodeling, is upregulated in @entity3 . However, the gingival expression of connective tissue growth factor ( @entity4 or @entity4 ), a @entity2 -upregulated gene, in @entity0 with @entity1 remains undetermined. Although both @entity4 / @entity4 and @entity2 increase the production of extracellular matrix, they have many different biological functions. Therefore, it is important to delineate the impact of @entity1 on gingival @entity4 / @entity4 expression. MATERIAL AND METHODS: Periodontal tissue specimens were collected from seven individuals without @entity1 (group 1) and from 14 with @entity1 (group 2). The expression of @entity4 and @entity2 mRNAs were quantified using real-time PCR. RESULTS: Analysis using the nonparametric Mann-Whitney U-test showed that the levels of expression of both @entity4 / @entity4 and @entity2 mRNAs were significantly increased in individuals with @entity1 compared with individuals without @entity1 . Furthermore, analysis using a nonparametric correlation (Spearman r) test showed a positive correlation between @entity2 and @entity4 / @entity4 mRNAs. CONCLUSION: The gingival expression levels of @entity4 / @entity4 and @entity2 mRNAs in individuals with @entity1 are upregulated and correlated.

title: Increased and correlated expression of connective tissue growth factor and XXXX in surgically removed periodontal tissues with @entity3 .

answer: @entity2


abstract: BACKGROUND: @entity5 is @entity2 and/or @entity7 of the gastrointestinal tract occurring as a complication of chemotherapy and radiation therapy, and affects about 50% of all @entity1 @entity0 . AIM: To assess the role of gut microbiota in the pathogenesis of @entity5 and the potential for manipulations of the microbiota to prevent and to treat @entity3 . METHODS: Search of the literature published in English using Medline, Scopus and the Cochrane Library, with main search terms 'intestinal microbiota', ' @entity8 ', ' @entity3 ', 'chemotherapy-induced @entity4 ', 'chemotherapy-induced @entity3 ', 'radiotherapy-induced @entity3 '. RESULTS: The gut microbiota plays a major role in the maintenance of intestinal homoeostasis and integrity. @entity0 receiving cytotoxic and radiation therapy exhibit marked changes in intestinal microbiota, with most frequently, decrease in Bifidobacterium, Clostridium cluster XIVa, Faecalibacterium prausnitzii, and increase in Enterobacteriaceae and Bacteroides. These modifications may contribute to the development of @entity3 , particularly @entity4 and @entity6 . The prevention of @entity1 therapy-induced @entity3 by probiotics has been investigated in randomised clinical trials with some promising results. Three of six trials reported a significantly decreased incidence of @entity4 . One trial reported a decrease in infectious complications. CONCLUSIONS: The gut microbiota may play a major role in the pathogenesis of @entity3 through the modification of intestinal barrier function, innate immunity and intestinal repair mechanisms. Better knowledge of these effects may lead to new therapeutic approaches and to the identification of predictive markers of @entity3 .

title: Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced XXXX - current evidence and potential clinical applications.

answer: @entity5


abstract: AIM: This study examined the relationship between hypothalamic-associated hormones and behavioural and @entity4 in @entity0 with low birthweight. METHODS: We included 100 @entity0 (mean age 9.7 years): 39 were born preterm at <32 gestational weeks, 28 were full-term, but small for gestational age, and 33 were full-term controls. Behavioural histories were analysed, together with fasting blood samples of leptin, @entity2 ), @entity6 , glucagon and @entity3 . RESULTS: Preterm @entity0 had lower @entity6 (p  =  0.01) and higher @entity2 than controls (p  <  0.05, adjusted for confounders), despite being significantly shorter than the predicted target height (p  <  0.001). More preterm @entity0 displayed @entity1 (38% versus 10%, p  <  0.001) and @entity4 (26% versus 8%, p  <  0.05) than full-term @entity0 . These disorders were associated with lower leptin (p  <  0.01), insulin (p  <  0.05) and @entity2 (p  <  0.05), but correlations between these hormones and leptin were similar among the groups. Combined behavioural and @entity4 were only observed in preterm @entity0 , who were also the shortest in height. CONCLUSION: Behavioural and @entity4 among preterm @entity0 were associated with low leptin, insulin and @entity2 . Low @entity6 in all preterm @entity0 indicated an increased dopaminergic tonus, which might inhibit body weight incrementation. This raises speculation about @entity5 insensitivity.

title: Preterm born 9-year-olds have elevated @entity2 and low XXXX , but levels vary with behavioural and @entity4 .

answer: @entity6


abstract: AIM: This study examined the relationship between hypothalamic-associated hormones and behavioural and @entity4 in @entity0 with low birthweight. METHODS: We included 100 @entity0 (mean age 9.7 years): 39 were born preterm at <32 gestational weeks, 28 were full-term, but small for gestational age, and 33 were full-term controls. Behavioural histories were analysed, together with fasting blood samples of leptin, @entity2 ), @entity6 , glucagon and @entity3 . RESULTS: Preterm @entity0 had lower @entity6 (p  =  0.01) and higher @entity2 than controls (p  <  0.05, adjusted for confounders), despite being significantly shorter than the predicted target height (p  <  0.001). More preterm @entity0 displayed @entity1 (38% versus 10%, p  <  0.001) and @entity4 (26% versus 8%, p  <  0.05) than full-term @entity0 . These disorders were associated with lower leptin (p  <  0.01), insulin (p  <  0.05) and @entity2 (p  <  0.05), but correlations between these hormones and leptin were similar among the groups. Combined behavioural and @entity4 were only observed in preterm @entity0 , who were also the shortest in height. CONCLUSION: Behavioural and @entity4 among preterm @entity0 were associated with low leptin, insulin and @entity2 . Low @entity6 in all preterm @entity0 indicated an increased dopaminergic tonus, which might inhibit body weight incrementation. This raises speculation about @entity5 insensitivity.

title: Preterm born 9-year-olds have elevated @entity2 and low @entity6 , but levels vary with behavioural and XXXX .

answer: @entity4


abstract: AIM: This study examined the relationship between hypothalamic-associated hormones and behavioural and @entity4 in @entity0 with low birthweight. METHODS: We included 100 @entity0 (mean age 9.7 years): 39 were born preterm at <32 gestational weeks, 28 were full-term, but small for gestational age, and 33 were full-term controls. Behavioural histories were analysed, together with fasting blood samples of leptin, @entity2 ), @entity6 , glucagon and @entity3 . RESULTS: Preterm @entity0 had lower @entity6 (p  =  0.01) and higher @entity2 than controls (p  <  0.05, adjusted for confounders), despite being significantly shorter than the predicted target height (p  <  0.001). More preterm @entity0 displayed @entity1 (38% versus 10%, p  <  0.001) and @entity4 (26% versus 8%, p  <  0.05) than full-term @entity0 . These disorders were associated with lower leptin (p  <  0.01), insulin (p  <  0.05) and @entity2 (p  <  0.05), but correlations between these hormones and leptin were similar among the groups. Combined behavioural and @entity4 were only observed in preterm @entity0 , who were also the shortest in height. CONCLUSION: Behavioural and @entity4 among preterm @entity0 were associated with low leptin, insulin and @entity2 . Low @entity6 in all preterm @entity0 indicated an increased dopaminergic tonus, which might inhibit body weight incrementation. This raises speculation about @entity5 insensitivity.

title: Preterm born 9-year-olds have elevated XXXX and low @entity6 , but levels vary with behavioural and @entity4 .

answer: @entity2


abstract: @entity7 ( @entity7 ) is a promising therapeutic approach for treating @entity8 . Past studies have shown that @entity7 reduces @entity1 response only in severe @entity4 model @entity0 . We worked to establish mild @entity4 model @entity0 , and investigated whether 'rush' @entity7 for 10 d improved the @entity1 response and biomarkers in these @entity0 . Balb/c @entity0 were sensitized to ovomucoid (OM) in alum. The rush @entity7 was done for 10 d. Oral OM challenge was used to determine the impact of @entity7 on the @entity1 response. We measured @entity1 biomarkers, such as vascular permeability in the skin, plasma levels of total IgE, OM-specific IgE, @entity9 and @entity10 and cytokines in splenocyte culture supernatant. @entity7 for 10 d did not improve @entity4 symptoms and increased vascular permeability. Total IgE in the plasma of @entity7 -treated @entity0 was significantly higher than in that of non-treated @entity0 . OM-specific @entity9 and @entity10 plasma levels were not significantly different between @entity7 -treated and non-treated @entity0 . Among the cytokine secretion of splenocyte from @entity7 -treated @entity0 , IFN-y and @entity6 were significantly lower than in non-treated @entity0 , and @entity2 and @entity3 were significantly higher. Total @entity5 in the @entity7 -treated group was not detected. The IFN-y/ @entity2 ratio of the @entity7 -treated group was about 1/8 that of the non-treated group. @entity7 for 10 d was not effective and some biomarkers showed negative responses in the mild @entity4 model @entity0 . We suggest @entity7 should be used very carefully as this treatment carries a risk of @entity4 for @entity0 with mild @entity4 .

title: Rush Oral Immunotherapy Does Not Reduce XXXX in @entity0 with Mild Allergy to Egg White Ovomucoid.

answer: @entity1


abstract: @entity7 ( @entity7 ) is a promising therapeutic approach for treating @entity8 . Past studies have shown that @entity7 reduces @entity1 response only in severe @entity4 model @entity0 . We worked to establish mild @entity4 model @entity0 , and investigated whether 'rush' @entity7 for 10 d improved the @entity1 response and biomarkers in these @entity0 . Balb/c @entity0 were sensitized to ovomucoid (OM) in alum. The rush @entity7 was done for 10 d. Oral OM challenge was used to determine the impact of @entity7 on the @entity1 response. We measured @entity1 biomarkers, such as vascular permeability in the skin, plasma levels of total IgE, OM-specific IgE, @entity9 and @entity10 and cytokines in splenocyte culture supernatant. @entity7 for 10 d did not improve @entity4 symptoms and increased vascular permeability. Total IgE in the plasma of @entity7 -treated @entity0 was significantly higher than in that of non-treated @entity0 . OM-specific @entity9 and @entity10 plasma levels were not significantly different between @entity7 -treated and non-treated @entity0 . Among the cytokine secretion of splenocyte from @entity7 -treated @entity0 , IFN-y and @entity6 were significantly lower than in non-treated @entity0 , and @entity2 and @entity3 were significantly higher. Total @entity5 in the @entity7 -treated group was not detected. The IFN-y/ @entity2 ratio of the @entity7 -treated group was about 1/8 that of the non-treated group. @entity7 for 10 d was not effective and some biomarkers showed negative responses in the mild @entity4 model @entity0 . We suggest @entity7 should be used very carefully as this treatment carries a risk of @entity4 for @entity0 with mild @entity4 .

title: Rush Oral Immunotherapy Does Not Reduce @entity1 in XXXX with Mild Allergy to Egg White Ovomucoid.

answer: @entity0


abstract: BACKGROUND: @entity2 genotype and aging have been identified as risk factors for @entity1 ( @entity1 ). In addition, @entity3 ( @entity3 ) might be a first clinical expression of the effect of @entity1 pathology on cognitive functioning. OBJECTIVE: To assess whether @entity2 genotype, age, @entity3 , and episodic memory are risk factors for high amyloid-b (Ab) burden in cognitively normal elderly. METHODS: 307 cognitively normal @entity0 (72.7    6.8 years, 53% female, 55% @entity3 ) from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study underwent amyloid PET and @entity2 genotyping. Logistic regression analyses were performed to determine the association of @entity2 genotype, age, @entity3 , and episodic memory with Ab pathology. RESULTS: Odds of high Ab burden were greater at an older age (OR=3.21; 95% CI=1.68-6.14), when @entity3 were present (OR=1.90; 95% CI=1.03-3.48), and for @entity2 carriers (OR=7.49; 95% CI=3.96-14.15), while episodic memory was not associated with odds of high Ab burden. Stratified analyses showed that odds of @entity3 for high Ab burden were increased in specifically @entity2 carriers (OR=4.58, 95% CI=1.83-11.49) and younger @entity0 (OR=3.73, 95% CI=1.39-10.01). CONCLUSION: Aging, @entity2 genotype, and @entity3 were associated with high Ab burden. @entity3 were especially indicative of high Ab burden in younger @entity0 and in @entity2 carriers. These findings suggest that selection based on the presence of @entity3 , @entity2 genotype and age may help identify healthy elderly @entity0 with high Ab burden eligible for secondary prevention trials.

title: Subjective Memory Complaints in XXXX Carriers are Associated with High Amyloid-b Burden.

answer: @entity2


abstract: BACKGROUND: Blunt @entity4 (BCI) may manifest as @entity4 or, more rarely, as pericardial or @entity3 . Computed tomography (CT) is performed in the vast majority of @entity1 @entity0 , but the imaging features of @entity4 are not well described. PURPOSE: To evaluate CT findings and associated injuries in @entity0 with clinically diagnosed BCI. MATERIALS AND METHODS: We identified 42 @entity0 with blunt @entity4 from our institution's electronic medical record. Clinical parameters, echocardiography results, and laboratory tests were recorded. Two blinded reviewers analyzed chest CTs performed in these @entity0 for @entity3 and associated injuries. RESULTS: CT findings of severe thoracic @entity1 are commonly present in @entity0 with severe BCI; 82% of @entity0 with ECG, cardiac enzyme, and echocardiographic evidence of BCI had abnormalities of the heart or pericardium on CT; 73% had anterior rib @entity2 , and 64% had pulmonary contusions. Sternal @entity2 were only seen in 36% of such @entity0 . However, @entity3 on CT is poorly sensitive for those @entity0 with @entity4 : 0% of right ventricular contusions and 22% of left ventricular contusions seen on echocardiography were identified on CT. CONCLUSION: CT signs of severe thoracic @entity1 are frequently present in @entity0 with severe BCI and should be regarded as indirect evidence of potential BCI. Direct CT findings of @entity3 , i.e. @entity3 , are poorly sensitive and should not be used as a screening tool. However, some left ventricular contusions can be seen on CT, and these @entity0 could undergo echocardiography or cardiac MRI to evaluate for wall motion abnormalities.

title: Imaging in blunt XXXX : Computed tomographic findings in @entity4 and associated injuries.

answer: @entity4


abstract: BACKGROUND: Blunt @entity4 (BCI) may manifest as @entity4 or, more rarely, as pericardial or @entity3 . Computed tomography (CT) is performed in the vast majority of @entity1 @entity0 , but the imaging features of @entity4 are not well described. PURPOSE: To evaluate CT findings and associated injuries in @entity0 with clinically diagnosed BCI. MATERIALS AND METHODS: We identified 42 @entity0 with blunt @entity4 from our institution's electronic medical record. Clinical parameters, echocardiography results, and laboratory tests were recorded. Two blinded reviewers analyzed chest CTs performed in these @entity0 for @entity3 and associated injuries. RESULTS: CT findings of severe thoracic @entity1 are commonly present in @entity0 with severe BCI; 82% of @entity0 with ECG, cardiac enzyme, and echocardiographic evidence of BCI had abnormalities of the heart or pericardium on CT; 73% had anterior rib @entity2 , and 64% had pulmonary contusions. Sternal @entity2 were only seen in 36% of such @entity0 . However, @entity3 on CT is poorly sensitive for those @entity0 with @entity4 : 0% of right ventricular contusions and 22% of left ventricular contusions seen on echocardiography were identified on CT. CONCLUSION: CT signs of severe thoracic @entity1 are frequently present in @entity0 with severe BCI and should be regarded as indirect evidence of potential BCI. Direct CT findings of @entity3 , i.e. @entity3 , are poorly sensitive and should not be used as a screening tool. However, some left ventricular contusions can be seen on CT, and these @entity0 could undergo echocardiography or cardiac MRI to evaluate for wall motion abnormalities.

title: Imaging in blunt @entity4 : Computed tomographic findings in XXXX and associated injuries.

answer: @entity4


abstract: BACKGROUND AND OBJECTIVE: @entity6 ( @entity6 ) is a major symptom of @entity7 ( @entity7 ). We assessed the spectrum of @entity5 symptoms and their potential correlates in a large prospective cohort of @entity7 individuals. METHODS: A standardized questionnaire was used in 378 @entity7 @entity0 for assessing @entity1 symptoms, trigger factors, age at first attack, frequency of attacks and associated symptoms. @entity2 and @entity4 were quantified. RESULTS: A total of 54.5% of individuals had a history of @entity5 in 84% of them; 62.4% of individuals with @entity6 were @entity0 and age at onset of @entity6 was lower in @entity0 than in @entity0 . @entity3 were experienced by 59.3% of individuals with @entity6 , and for 19.7% of @entity0 with @entity6 the aura was never accompanied by @entity1 . @entity6 was the inaugural manifestation in 41% of symptomatic @entity0 and an isolated symptom in 12.1% of individuals. Slightly higher MMSE and MDRS scores and lower Rankin score were detected in the @entity6 group. CONCLUSION: @entity6 is observed in almost half of all @entity7 @entity0 . @entity3 are reported by more than one in two of them. @entity6 is often inaugural, can remain isolated and is not associated with the severity of the disorder.

title: Prevalence and characteristics of @entity5 in XXXX .

answer: @entity7


abstract: BACKGROUND AND OBJECTIVE: @entity6 ( @entity6 ) is a major symptom of @entity7 ( @entity7 ). We assessed the spectrum of @entity5 symptoms and their potential correlates in a large prospective cohort of @entity7 individuals. METHODS: A standardized questionnaire was used in 378 @entity7 @entity0 for assessing @entity1 symptoms, trigger factors, age at first attack, frequency of attacks and associated symptoms. @entity2 and @entity4 were quantified. RESULTS: A total of 54.5% of individuals had a history of @entity5 in 84% of them; 62.4% of individuals with @entity6 were @entity0 and age at onset of @entity6 was lower in @entity0 than in @entity0 . @entity3 were experienced by 59.3% of individuals with @entity6 , and for 19.7% of @entity0 with @entity6 the aura was never accompanied by @entity1 . @entity6 was the inaugural manifestation in 41% of symptomatic @entity0 and an isolated symptom in 12.1% of individuals. Slightly higher MMSE and MDRS scores and lower Rankin score were detected in the @entity6 group. CONCLUSION: @entity6 is observed in almost half of all @entity7 @entity0 . @entity3 are reported by more than one in two of them. @entity6 is often inaugural, can remain isolated and is not associated with the severity of the disorder.

title: Prevalence and characteristics of XXXX in @entity7 .

answer: @entity5


abstract: OBJECTIVE: To find out the clinical and pathological characteristics in acute @entity2 . METHODS: A retrospective clinical analysis was made on 742 cases of @entity3 from January 2003 to December 2012. All cases underwent appendectomy. @entity0 were allocated to the acute @entity2 (ACA) group and the acute uncomplicated @entity4 group based on pathological reports. The      test was used to check for differences between proportions. Multivariate analysis was made through the Logistic regression. RESULTS: Of 742 @entity0 , 533 were allocated to the ACA group, including acute @entity4 306 @entity0 , @entity3 100 patiets, @entity4 with perforation 59 @entity0 , @entity4 with @entity5 formation 6 @entity0 and @entity4 with @entity1 5 @entity0 . Statistical result shows that the @entity0 of ACA group usually had higher toal WBC count, local or diffuse muscle guarding, intraluminal stercolith or periappendiceal fluid. Logistic regression also indicated that ACA were mathematically related to high level white blood cell count (>20   10   /L, OR = 2.717, 95%CI: 1.834-4.027, P < 0.05), local or diffuse muscle guarding (OR = 1.649, 95%CI: 1.047-2.597, P < 0.05), intraluminal stercolith (OR = 2.939, 95%CI: 1.607-5.377, P < 0.05) and periappendiceal fluid (OR = 3.273, 95%CI: 1.424-7.525, P < 0.05). CONCLUSIONS: @entity0 with high level WBC count, local or diffuse muscle guarding, intraluminal stercolith or periappendiceal fluid are likely suffering from acute @entity2 . Appendectomy must be considered as first-line therapy other than conservative antibiotic therapy under these situations.

title: [Clinical and pathological characteristics in acute XXXX ].

answer: @entity2


abstract: We aimed to clarify the differences between the estimated rectal dose (ERD) and the @entity1 ( @entity1 ) and @entity5 ( @entity5 ) to the rectum during @entity4 ( @entity4 ) brachytherapy, and to predict @entity1 from the @entity3 ( @entity3 ) or the rectal dose-volume parameters (RDVPs). ERD, @entity1 , and @entity5 were assessed with a rectal dosimeter during @entity4 brachytherapy of 18  Gy given in two fractions to 110 @entity0 (48 hormone recipients, 62 hormone-na  ve @entity0 ) with @entity2 . The correlations between @entity1 and @entity3 , and between @entity1 and RDVP (D 2ml-D 5ml) were investigated. ERD (mean      SD) was 219      44  cGy, @entity1 was 255      52  cGy, and @entity5 was 298      63  cGy, which differed significantly (p  <  0.001). The correlation coefficients between ERD and @entity1 , and between @entity1 and @entity5 , were 0.82 and 0.78, respectively. @entity5 was equivalent to 118      16  % @entity1 . The measured doses were significantly greater in the hormone recipients than in the hormone-na  ve @entity0 (p  <  0.001). The increase in @entity1 correlated with the increases in @entity3 and in RDVPs. The correlation coefficients between @entity3 and @entity1 in all of the @entity0 , in the hormone recipients, and in the hormone-na  ve @entity0 were 0.61, 0.64, and 0.64, respectively, whereas that between RDVPs and @entity1 was <0.53. In conclusion, the dose to the rectum increased with time and was correlated with the increases in @entity3 and RDVPs. The correlation coefficient between @entity1 and @entity3 was greater than that between @entity1 and RDVPs.

title: Radiation dose to rectum in XXXX brachytherapy with a single implant and two fractions for @entity2 , and its prediction by @entity3 .

answer: @entity4


abstract: We aimed to clarify the differences between the estimated rectal dose (ERD) and the @entity1 ( @entity1 ) and @entity5 ( @entity5 ) to the rectum during @entity4 ( @entity4 ) brachytherapy, and to predict @entity1 from the @entity3 ( @entity3 ) or the rectal dose-volume parameters (RDVPs). ERD, @entity1 , and @entity5 were assessed with a rectal dosimeter during @entity4 brachytherapy of 18  Gy given in two fractions to 110 @entity0 (48 hormone recipients, 62 hormone-na  ve @entity0 ) with @entity2 . The correlations between @entity1 and @entity3 , and between @entity1 and RDVP (D 2ml-D 5ml) were investigated. ERD (mean      SD) was 219      44  cGy, @entity1 was 255      52  cGy, and @entity5 was 298      63  cGy, which differed significantly (p  <  0.001). The correlation coefficients between ERD and @entity1 , and between @entity1 and @entity5 , were 0.82 and 0.78, respectively. @entity5 was equivalent to 118      16  % @entity1 . The measured doses were significantly greater in the hormone recipients than in the hormone-na  ve @entity0 (p  <  0.001). The increase in @entity1 correlated with the increases in @entity3 and in RDVPs. The correlation coefficients between @entity3 and @entity1 in all of the @entity0 , in the hormone recipients, and in the hormone-na  ve @entity0 were 0.61, 0.64, and 0.64, respectively, whereas that between RDVPs and @entity1 was <0.53. In conclusion, the dose to the rectum increased with time and was correlated with the increases in @entity3 and RDVPs. The correlation coefficient between @entity1 and @entity3 was greater than that between @entity1 and RDVPs.

title: Radiation dose to rectum in @entity4 brachytherapy with a single implant and two fractions for XXXX , and its prediction by @entity3 .

answer: @entity2


abstract: We aimed to clarify the differences between the estimated rectal dose (ERD) and the @entity1 ( @entity1 ) and @entity5 ( @entity5 ) to the rectum during @entity4 ( @entity4 ) brachytherapy, and to predict @entity1 from the @entity3 ( @entity3 ) or the rectal dose-volume parameters (RDVPs). ERD, @entity1 , and @entity5 were assessed with a rectal dosimeter during @entity4 brachytherapy of 18  Gy given in two fractions to 110 @entity0 (48 hormone recipients, 62 hormone-na  ve @entity0 ) with @entity2 . The correlations between @entity1 and @entity3 , and between @entity1 and RDVP (D 2ml-D 5ml) were investigated. ERD (mean      SD) was 219      44  cGy, @entity1 was 255      52  cGy, and @entity5 was 298      63  cGy, which differed significantly (p  <  0.001). The correlation coefficients between ERD and @entity1 , and between @entity1 and @entity5 , were 0.82 and 0.78, respectively. @entity5 was equivalent to 118      16  % @entity1 . The measured doses were significantly greater in the hormone recipients than in the hormone-na  ve @entity0 (p  <  0.001). The increase in @entity1 correlated with the increases in @entity3 and in RDVPs. The correlation coefficients between @entity3 and @entity1 in all of the @entity0 , in the hormone recipients, and in the hormone-na  ve @entity0 were 0.61, 0.64, and 0.64, respectively, whereas that between RDVPs and @entity1 was <0.53. In conclusion, the dose to the rectum increased with time and was correlated with the increases in @entity3 and RDVPs. The correlation coefficient between @entity1 and @entity3 was greater than that between @entity1 and RDVPs.

title: Radiation dose to rectum in @entity4 brachytherapy with a single implant and two fractions for @entity2 , and its prediction by XXXX .

answer: @entity3


abstract: BACKGROUND: An important challenge in @entity1 biology is to computationally screen mutations in @entity1 cells, separating those that might drive @entity1 initiation and progression, from the much larger number of bystanders. Since mutations are large in number and diverse in type, the frequency of any particular mutation pattern across a set of samples is low. This makes statistical distinctions and reproducibility across different populations difficult to establish. RESULTS: In this paper we develop a novel method that promises to partially ameliorate these problems. The basic idea is although mutations are highly heterogeneous and vary from one sample to another, the processes that are disrupted when cells undergo transformation tend to be invariant across a population for a particular @entity1 or @entity1 subtype. Specifically, we focus on finding mutated pathway-groups that are invariant across samples of @entity0 subtypes. The identification of informative pathway-groups consists of two steps. The first is identification of pathways significantly enriched in genes containing non-synonymous mutations; the second uses pathways so identified to find groups that are functionally related in the largest number of samples. An application to 4 subtypes of @entity0 identified pathway-groups that can highly explicate a particular subtype and rich in processes associated with transformation. CONCLUSIONS: In contrast to previous methods that identify pathways across a set of samples without any further validation, we show that mutated pathway-groups can be found in each @entity0 subtype and that such groups are invariant across the majority of samples. The algorithm is available at http://www.visantnet.org/misi/ @entity2 .

title: Identification of collaborative driver pathways in XXXX .

answer: @entity0


abstract: Evaluation of: Hampton DA, Lee TH, Diggs BJ, McCully SP, Schreiber MA. A predictive model of early mortality in @entity1 @entity0 . Am. J. Surg. 207(5), 642-647 (2014). In their prospective multi-centred observational study, Hampton et al. tested the ability of rapid thromboelastography (r-TEG) to predict mortality in @entity1 @entity0 . A total of 795 @entity0 were assessed. The authors analysed both @entity0 demographic and physiological measures. Validation of variables that significantly related to mortality was subsequently undertaken. Ly30 (a measurement of the degree of clot lysis over 30 min) was observed to be a predictor of 24-h mortality in @entity1 (odds ratio 3.7 p = 0.03). This was incorporated with haemoglobin level, international normalized ratio, Glasgow @entity2 Score and the presence of penetrating injury to form their five-variable mortality prediction model. Hampton et al. conclude that the correlation between r-TEG measurements and @entity1 mortality makes it a useful tool in mortality prediction. The report highlights the importance of using this point-of-care coagulation assessment machine in mortality prediction for @entity1 @entity0 .

title: The role of rapid thromboelastography in XXXX .

answer: @entity1


abstract: PURPOSE: We assessed the association between a family history of @entity1 and risk of @entity5 among individuals aged 40-49 years. METHODS: The study population consisted of subjects, aged in their 40s, who underwent colonoscopy. Their family histories of @entity1 were collected with a self-administered questionnaire. A logistic regression model was used to assess the association between a family history of @entity1 and the risk of @entity4 . RESULTS: In total, 2275 @entity0 were included in the study. Univariate analysis showed that old age, male sex, current cigarette smoking, BMI>25kg/m(2), and a family history of @entity2 ( @entity2 ) were risk factors for the development of sporadic @entity6 in these @entity0 . A multivariate analysis showed that a family history of @entity2 was associated with @entity3 development. A family history of @entity2 was also a risk factor for advanced and multiple @entity3 . CONCLUSIONS: This study shows that a family history of @entity2 is a risk factor for advanced and multiple @entity5 in @entity0 in their 40s. These results support earlier screening for @entity2 in individuals with a family history of @entity2 .

title: Association between family history of @entity1 with XXXX in 40s aged relative @entity0 .

answer: @entity6


abstract: PURPOSE: We assessed the association between a family history of @entity1 and risk of @entity5 among individuals aged 40-49 years. METHODS: The study population consisted of subjects, aged in their 40s, who underwent colonoscopy. Their family histories of @entity1 were collected with a self-administered questionnaire. A logistic regression model was used to assess the association between a family history of @entity1 and the risk of @entity4 . RESULTS: In total, 2275 @entity0 were included in the study. Univariate analysis showed that old age, male sex, current cigarette smoking, BMI>25kg/m(2), and a family history of @entity2 ( @entity2 ) were risk factors for the development of sporadic @entity6 in these @entity0 . A multivariate analysis showed that a family history of @entity2 was associated with @entity3 development. A family history of @entity2 was also a risk factor for advanced and multiple @entity3 . CONCLUSIONS: This study shows that a family history of @entity2 is a risk factor for advanced and multiple @entity5 in @entity0 in their 40s. These results support earlier screening for @entity2 in individuals with a family history of @entity2 .

title: Association between family history of XXXX with @entity6 in 40s aged relative @entity0 .

answer: @entity1


abstract: PURPOSE: We assessed the association between a family history of @entity1 and risk of @entity5 among individuals aged 40-49 years. METHODS: The study population consisted of subjects, aged in their 40s, who underwent colonoscopy. Their family histories of @entity1 were collected with a self-administered questionnaire. A logistic regression model was used to assess the association between a family history of @entity1 and the risk of @entity4 . RESULTS: In total, 2275 @entity0 were included in the study. Univariate analysis showed that old age, male sex, current cigarette smoking, BMI>25kg/m(2), and a family history of @entity2 ( @entity2 ) were risk factors for the development of sporadic @entity6 in these @entity0 . A multivariate analysis showed that a family history of @entity2 was associated with @entity3 development. A family history of @entity2 was also a risk factor for advanced and multiple @entity3 . CONCLUSIONS: This study shows that a family history of @entity2 is a risk factor for advanced and multiple @entity5 in @entity0 in their 40s. These results support earlier screening for @entity2 in individuals with a family history of @entity2 .

title: Association between family history of @entity1 with @entity6 in 40s aged relative XXXX .

answer: @entity0


abstract: BACKGROUND: A number of studies have reported relationships of @entity1 RsaI/ @entity3 polymorphisms with susceptibility to @entity0 in Chinese population. However, the epidemiologic results have been conflictive rather than conclusive. The purpose of this study was to address the associations of @entity1 RsaI/ @entity3 polymorphisms with @entity0 risk in Chinese population comprehensively. MATERIALS AND METHODS: Systematic searches were conducted in the PubMed, Science Direct, Elsevier, CNKI and Chinese Biomedical Literature Databases. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of association. RESULTS: Overall, we observed a @entity0 risk among subjects carrying @entity1 RsaI/ @entity3 c1/ c2 and @entity2 +c2/c2 genotypes (OR=0.76, 95%CI: 0.64-0.90 and OR=0.78, 95%CI: 0.66-0.93, respectively), as compared with subjects carrying the c1/c1 genotype. In subgroup analysis, we observed a @entity0 risk among @entity2 carriers in hospital-based studies (OR=0.81, 95%CI: 0.68-0.98) and among carriers with c1/ c2 and @entity2 +c2/c2 genotypes in population-based studies(OR=0.57, 95%CI: 0.42-0.79 and OR=0.58, 95%CI: 0.43-0.79, respectively), as compared with subjects carrying the c1/c1 genotype. Limiting the analysis to studies with controls in Hardy-Weinberg equilibrium (HWE), we similarly observed a @entity0 risk among @entity2 and @entity2 +c2/c2 carriers (OR=0.73, 95%CI: 0.60-0.88 and OR=0.73, 95%CI: 0.60-0.88, respectively), as compared with c1/c1. CONCLUSIONS: Our results suggested that @entity1 RsaI/ @entity3 @entity2 and @entity2 +c2/c2 variants might be a protective factor for developing @entity0 in Chinese population. Further well-designed studies with larger sample size are required to verify our findings.

title: Updated meta-analysis of the association between XXXX RsaI/ @entity3 polymorphisms and @entity0 risk in Chinese population.

answer: @entity1


abstract: BACKGROUND: A number of studies have reported relationships of @entity1 RsaI/ @entity3 polymorphisms with susceptibility to @entity0 in Chinese population. However, the epidemiologic results have been conflictive rather than conclusive. The purpose of this study was to address the associations of @entity1 RsaI/ @entity3 polymorphisms with @entity0 risk in Chinese population comprehensively. MATERIALS AND METHODS: Systematic searches were conducted in the PubMed, Science Direct, Elsevier, CNKI and Chinese Biomedical Literature Databases. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of association. RESULTS: Overall, we observed a @entity0 risk among subjects carrying @entity1 RsaI/ @entity3 c1/ c2 and @entity2 +c2/c2 genotypes (OR=0.76, 95%CI: 0.64-0.90 and OR=0.78, 95%CI: 0.66-0.93, respectively), as compared with subjects carrying the c1/c1 genotype. In subgroup analysis, we observed a @entity0 risk among @entity2 carriers in hospital-based studies (OR=0.81, 95%CI: 0.68-0.98) and among carriers with c1/ c2 and @entity2 +c2/c2 genotypes in population-based studies(OR=0.57, 95%CI: 0.42-0.79 and OR=0.58, 95%CI: 0.43-0.79, respectively), as compared with subjects carrying the c1/c1 genotype. Limiting the analysis to studies with controls in Hardy-Weinberg equilibrium (HWE), we similarly observed a @entity0 risk among @entity2 and @entity2 +c2/c2 carriers (OR=0.73, 95%CI: 0.60-0.88 and OR=0.73, 95%CI: 0.60-0.88, respectively), as compared with c1/c1. CONCLUSIONS: Our results suggested that @entity1 RsaI/ @entity3 @entity2 and @entity2 +c2/c2 variants might be a protective factor for developing @entity0 in Chinese population. Further well-designed studies with larger sample size are required to verify our findings.

title: Updated meta-analysis of the association between @entity1 RsaI/ XXXX polymorphisms and @entity0 risk in Chinese population.

answer: @entity3


abstract: BACKGROUND: A number of studies have reported relationships of @entity1 RsaI/ @entity3 polymorphisms with susceptibility to @entity0 in Chinese population. However, the epidemiologic results have been conflictive rather than conclusive. The purpose of this study was to address the associations of @entity1 RsaI/ @entity3 polymorphisms with @entity0 risk in Chinese population comprehensively. MATERIALS AND METHODS: Systematic searches were conducted in the PubMed, Science Direct, Elsevier, CNKI and Chinese Biomedical Literature Databases. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of association. RESULTS: Overall, we observed a @entity0 risk among subjects carrying @entity1 RsaI/ @entity3 c1/ c2 and @entity2 +c2/c2 genotypes (OR=0.76, 95%CI: 0.64-0.90 and OR=0.78, 95%CI: 0.66-0.93, respectively), as compared with subjects carrying the c1/c1 genotype. In subgroup analysis, we observed a @entity0 risk among @entity2 carriers in hospital-based studies (OR=0.81, 95%CI: 0.68-0.98) and among carriers with c1/ c2 and @entity2 +c2/c2 genotypes in population-based studies(OR=0.57, 95%CI: 0.42-0.79 and OR=0.58, 95%CI: 0.43-0.79, respectively), as compared with subjects carrying the c1/c1 genotype. Limiting the analysis to studies with controls in Hardy-Weinberg equilibrium (HWE), we similarly observed a @entity0 risk among @entity2 and @entity2 +c2/c2 carriers (OR=0.73, 95%CI: 0.60-0.88 and OR=0.73, 95%CI: 0.60-0.88, respectively), as compared with c1/c1. CONCLUSIONS: Our results suggested that @entity1 RsaI/ @entity3 @entity2 and @entity2 +c2/c2 variants might be a protective factor for developing @entity0 in Chinese population. Further well-designed studies with larger sample size are required to verify our findings.

title: Updated meta-analysis of the association between @entity1 RsaI/ @entity3 polymorphisms and XXXX risk in Chinese population.

answer: @entity0


abstract: A @entity0 presented with a frontal nodule of the scalp. Histopathological examination revealed a myxomatous multilobulate @entity1 composed of epithelioid cells with variable pleomorphism. Perineurium-like structures were seen but only around isolated lobules located at the @entity1 periphery. Electron microscopy revealed polygonal cells and cells with elongated cytoplasmic processes. Many cells had myelinoid figures. A basement membrane-like lamina was noted around some cells. Some of the @entity1 cells were immunoreactive for @entity2 . This finding suggests that the @entity1 cells are of schwannian type. @entity3 of Gallager and Helwig is a rare, probably @entity1 with fairly distinctive histopathologic characteristics. It appears to be a variant of @entity3 .

title: XXXX of Gallager and Helwig ( @entity3 variant): report of a case with electron microscopic and immunohistochemical studies.

answer: @entity3


abstract: A @entity0 presented with a frontal nodule of the scalp. Histopathological examination revealed a myxomatous multilobulate @entity1 composed of epithelioid cells with variable pleomorphism. Perineurium-like structures were seen but only around isolated lobules located at the @entity1 periphery. Electron microscopy revealed polygonal cells and cells with elongated cytoplasmic processes. Many cells had myelinoid figures. A basement membrane-like lamina was noted around some cells. Some of the @entity1 cells were immunoreactive for @entity2 . This finding suggests that the @entity1 cells are of schwannian type. @entity3 of Gallager and Helwig is a rare, probably @entity1 with fairly distinctive histopathologic characteristics. It appears to be a variant of @entity3 .

title: @entity3 of Gallager and Helwig ( XXXX variant): report of a case with electron microscopic and immunohistochemical studies.

answer: @entity3


abstract: BACKGROUND: Vitiligo has been classified clinically into segmental @entity3 (SV) and nonsegmental @entity3 (NSV) and may also be associated with @entity2 . OBJECTIVES: We examined cochlear function in ears of individuals with SV and NSV, including subjects with facial and @entity1 , and in @entity0 who have SV with unilateral facial involvement. METHODS: This study included 25 @entity0 with SV and 28 @entity0 with NSV. Fifteen age- and sex-matched healthy individuals served as controls. Cochlear function was studied using the distortion product otoacoustic emissions (DPOAEs). Data were analysed using SPSS. RESULTS: Sixty-four ears (60%) of @entity0 with @entity3 had @entity4 while the control group exhibited no abnormalities. On comparing the @entity4 of @entity0 with SV with @entity0 with NSV, no statistically significant difference was found. The ears on both sides, affected and unaffected by @entity3 , in @entity0 with SV showed @entity4 with no statistically significant difference in DPOAE. To determine the effect of the lesion side on cochlear function, we compared DPOAE amplitude using Student's t-test. The comparisons included NSV of the face vs. NSV on other areas, NSV of the face vs. SV of the face and SV of the face vs. SV of other areas. No statistically significant difference was found in these comparisons. CONCLUSIONS: @entity4 is common in both NSV and SV and does not reflect the appearance of @entity3 in the skin. Our results underscore the important role of melanocytes and melanin in cochlear function, and suggest that the @entity4 in SV point to the presence of additional nonsegmental pathophysiological events underlying all forms of @entity3 .

title: Most individuals with either segmental or nonsegmental @entity3 display evidence of bilateral XXXX .

answer: @entity4


abstract: BACKGROUND: Vitiligo has been classified clinically into segmental @entity3 (SV) and nonsegmental @entity3 (NSV) and may also be associated with @entity2 . OBJECTIVES: We examined cochlear function in ears of individuals with SV and NSV, including subjects with facial and @entity1 , and in @entity0 who have SV with unilateral facial involvement. METHODS: This study included 25 @entity0 with SV and 28 @entity0 with NSV. Fifteen age- and sex-matched healthy individuals served as controls. Cochlear function was studied using the distortion product otoacoustic emissions (DPOAEs). Data were analysed using SPSS. RESULTS: Sixty-four ears (60%) of @entity0 with @entity3 had @entity4 while the control group exhibited no abnormalities. On comparing the @entity4 of @entity0 with SV with @entity0 with NSV, no statistically significant difference was found. The ears on both sides, affected and unaffected by @entity3 , in @entity0 with SV showed @entity4 with no statistically significant difference in DPOAE. To determine the effect of the lesion side on cochlear function, we compared DPOAE amplitude using Student's t-test. The comparisons included NSV of the face vs. NSV on other areas, NSV of the face vs. SV of the face and SV of the face vs. SV of other areas. No statistically significant difference was found in these comparisons. CONCLUSIONS: @entity4 is common in both NSV and SV and does not reflect the appearance of @entity3 in the skin. Our results underscore the important role of melanocytes and melanin in cochlear function, and suggest that the @entity4 in SV point to the presence of additional nonsegmental pathophysiological events underlying all forms of @entity3 .

title: Most individuals with either segmental or nonsegmental XXXX display evidence of bilateral @entity4 .

answer: @entity3


abstract: OBJECTIVE: @entity1 ( @entity1 ) type II is increasing rapidly worldwide. @entity0 with @entity1 II have a greater atherosclerotic burden and higher risk of developing @entity3 . @entity2 has been proposed as the main cause for the high risk of @entity4 in @entity1 II. In this study, we compared markers of @entity2 and fibrous repair in plaques from subjects with and without @entity1 II. APPROACH AND RESULTS: Carotid endarterectomy specimens were obtained from 63 @entity0 with and 131 without @entity1 . Plaque structure, connective tissue proteins, inflammatory cells, and markers were analyzed by immunohistochemistry, ELISA, Mesoscale, and Luminex technology. Carotid plaques from @entity1 had lower levels of extracellular matrix proteins, @entity6 , and collagen, which are critical for plaque stability. Plaques from @entity1 had reduced levels of platelet-derived growth factor and @entity5 , both important for tissue repair. No differences were observed in inflammatory markers in plaques from @entity1 and nondiabetic @entity0 . CONCLUSION: This study suggests that @entity4 in subjects with @entity1 II are more prone to rupture because of impaired repair responses rather than to @entity2 . Although this study did not have a mechanistic design, our findings suggest that targeting impaired repair responses in carotid plaques may help to increase our understanding of @entity4 development and vulnerability in @entity0 with @entity1 II.

title: Impaired fibrous repair: a possible contributor to XXXX vulnerability in @entity0 with type II diabetes.

answer: @entity4


abstract: OBJECTIVE: @entity1 ( @entity1 ) type II is increasing rapidly worldwide. @entity0 with @entity1 II have a greater atherosclerotic burden and higher risk of developing @entity3 . @entity2 has been proposed as the main cause for the high risk of @entity4 in @entity1 II. In this study, we compared markers of @entity2 and fibrous repair in plaques from subjects with and without @entity1 II. APPROACH AND RESULTS: Carotid endarterectomy specimens were obtained from 63 @entity0 with and 131 without @entity1 . Plaque structure, connective tissue proteins, inflammatory cells, and markers were analyzed by immunohistochemistry, ELISA, Mesoscale, and Luminex technology. Carotid plaques from @entity1 had lower levels of extracellular matrix proteins, @entity6 , and collagen, which are critical for plaque stability. Plaques from @entity1 had reduced levels of platelet-derived growth factor and @entity5 , both important for tissue repair. No differences were observed in inflammatory markers in plaques from @entity1 and nondiabetic @entity0 . CONCLUSION: This study suggests that @entity4 in subjects with @entity1 II are more prone to rupture because of impaired repair responses rather than to @entity2 . Although this study did not have a mechanistic design, our findings suggest that targeting impaired repair responses in carotid plaques may help to increase our understanding of @entity4 development and vulnerability in @entity0 with @entity1 II.

title: Impaired fibrous repair: a possible contributor to @entity4 vulnerability in XXXX with type II diabetes.

answer: @entity0


abstract: BACKGROUND: Rituximab, a monoclonal anti- @entity3 antibody, has been used with encouraging results in @entity5 . We describe herein refractory cases of @entity5 (n = 23) and @entity5 foliaceus (n = 1) treated with rituximab in addition to @entity1 and immunosuppressants. AIMS: To assess the response to treatment, the duration of clinical remission, serology of the response and adverse effects of rituximab in @entity5 @entity0 . METHODS: We recorded observations of 24 @entity0 with @entity5 having either refractory disease in spite of high dose of @entity1 and immunosuppressants, corticosteroid-dependent disease, strong contraindications to @entity2 , or severe disease. The @entity0 were treated with infusions of one injection per week for three consecutive weeks of 375 mg of rituximab per m    of body-surface area. One similar infusion was repeated after 3 months of 3 rd dose. We observed the clinical outcome after 6 months of 3 rd dose of rituximab and looked for complete healing of @entity4 (complete remission). OBSERVATIONS: After follow-up of 7-24 months, five @entity0 showed only partial improvement while 19 of 24 @entity0 had a complete remission 3 months after rituximab. Of these 19 @entity0 , 12 @entity0 achieved complete remission and are off all systemic therapy, and the rest are continuing with no or low dose of @entity1 with immunosuppressants. Two @entity0 relapsed after initial improvement; one was given moderate dose of oral @entity1 and immunosuppressant and the other was given repeat single dose of rituximab to control relapse. CONCLUSION: Rituximab is able to induce a prolonged clinical remission in @entity5 after a single course of four infusions. The high cost and limited knowledge of long term adverse effects are limitations to the use of this biologic agent.

title: Intermediate doses of rituximab used as adjuvant therapy in refractory XXXX .

answer: @entity5


abstract: OBJECTIVE: Knowledge and attitude regarding @entity1 ( @entity1 ) is one of the important parameters for acceptance of @entity1 as a safe and effective treatment option. Several factors shape the knowledge and attitude of general @entity0 such as previous experience of @entity1 , sources of their information about @entity1 and prevailing myths about @entity1 . The present study attempted to examine the knowledge and attitude concerning @entity1 among @entity0 with @entity2 and their relatives. MATERIALS AND METHODS: Knowledge and attitudes regarding @entity1 were assessed using the Bengali version of the @entity1 knowledge and attitude questionnaires, between 100 clinically stable @entity0 with mental illnesses and their healthy relatives. RESULTS: Majority of the @entity0 and relatives were unaware of the basic facts about @entity1 . Relatives were somewhat better informed and more positive about @entity1 than @entity0 , but the differences between the two groups were not significant. Previous experience of @entity1 did not have any major impact in knowledge and attitude in both @entity0 and relative groups. @entity0 obtained information, mostly from media (44%), doctors (23%), and from personal experiences (13%). On the other hand, relatives obtained information almost equally from media (26%), doctors (27%), and experience of friends or relatives (28%). No significant difference was observed in knowledge and attitude in @entity0 who had obtained their facts from doctors (n=23) and from other sources (n=77). Among relatives, those who had obtained their information from doctors (n=27) were better informed than those who had obtained so from other sources (n=73). CONCLUSIONS: Since @entity0 and relatives have poor knowledge and negative attitude toward @entity1 , medical professionals should impart proper information about @entity1 to @entity0 and relatives to increase the acceptability of this treatment.

title: Knowledge and Attitude of @entity0 with XXXX and their Relatives Toward Electroconvulsive Therapy.

answer: @entity2


abstract: OBJECTIVE: Knowledge and attitude regarding @entity1 ( @entity1 ) is one of the important parameters for acceptance of @entity1 as a safe and effective treatment option. Several factors shape the knowledge and attitude of general @entity0 such as previous experience of @entity1 , sources of their information about @entity1 and prevailing myths about @entity1 . The present study attempted to examine the knowledge and attitude concerning @entity1 among @entity0 with @entity2 and their relatives. MATERIALS AND METHODS: Knowledge and attitudes regarding @entity1 were assessed using the Bengali version of the @entity1 knowledge and attitude questionnaires, between 100 clinically stable @entity0 with mental illnesses and their healthy relatives. RESULTS: Majority of the @entity0 and relatives were unaware of the basic facts about @entity1 . Relatives were somewhat better informed and more positive about @entity1 than @entity0 , but the differences between the two groups were not significant. Previous experience of @entity1 did not have any major impact in knowledge and attitude in both @entity0 and relative groups. @entity0 obtained information, mostly from media (44%), doctors (23%), and from personal experiences (13%). On the other hand, relatives obtained information almost equally from media (26%), doctors (27%), and experience of friends or relatives (28%). No significant difference was observed in knowledge and attitude in @entity0 who had obtained their facts from doctors (n=23) and from other sources (n=77). Among relatives, those who had obtained their information from doctors (n=27) were better informed than those who had obtained so from other sources (n=73). CONCLUSIONS: Since @entity0 and relatives have poor knowledge and negative attitude toward @entity1 , medical professionals should impart proper information about @entity1 to @entity0 and relatives to increase the acceptability of this treatment.

title: Knowledge and Attitude of XXXX with @entity2 and their Relatives Toward Electroconvulsive Therapy.

answer: @entity0


abstract: BACKGROUND: Care provided by student doctors and nurses is well received by @entity0 in hospital and primary care settings. Whether the same is true for aged care residents of nursing homes with mild @entity1 and their family members is unknown. OBJECTIVE: To investigate the perspectives of aged care residents with mild @entity1 and their family members on interdisciplinary student placements in two residential aged care facilities (RACF) in Tasmania. DESIGN, SETTING AND @entity0 : A mixed methods design was employed with both qualitative and quantitative data collected. All @entity0 were interviewed and completed a questionnaire on residents' quality of life, during or after a period of student placements in each facility (October-November, 2012). Qualitative data were coded for themes following a grounded theory approach, and quantitative data were analysed using SPSS. RESULTS: Twenty-one @entity0 (13 residents and 8 family members) were recruited. Four themes were identified from the qualitative data and included (i) increased social interaction and facility vibrancy; (ii) community service and personal development, (iii) vulnerability and sensitivity (learning to care) and (iv) increased capacity and the confidence of enhanced care. Residents' quality of life was reported to be mostly good in the presence of the students, despite their high care needs. CONCLUSION: Residents with mild @entity1 and their family members perceive a wide array of benefits of student provided care in RACFs including increased social interaction. Future quantitative research should focus on whether changes in care occur for residents as a result of student involvement.

title: Residents with mild XXXX and family members report health students 'enhance capacity of care' and bring 'a new breath of life' in two aged care facilities in Tasmania.

answer: @entity1


abstract: OBJECTIVE: To report the health care experiences of 34 individuals with coexisting @entity3 ( @entity3 ) and @entity4 . DESIGN: Narrative inquiry qualitative study of 90-minute interviews. SETTING: Midwest metropolitan @entity2 clinic. SUBJECTS: All individuals had @entity3 and were treated for @entity3 with @entity2 . They all self-identified as having @entity1 longer than 6 months. METHODS: This qualitative design allowed exploration of how @entity0 made sense of events related to living with @entity3 and @entity4 . Narrative inquiry gives a consistent story from the @entity0 ' perspective, and researchers can perform additional analysis using the storyline. Thematic analysis occurred of their health care experiences. RESULTS: Results revealed that @entity0 1) spoke about how they used deception to obtain opioids when their drug cravings were out of control; 2) were disturbed by health care providers having little understanding or ability to help them with their painful condition; 3) felt they wanted to abuse opioids again when receiving poor treatment by the health care team; 4) related what went well in their health care to help them maintain their sobriety; and 5) recommended improvements on health care interventions that included effective treatment of @entity1 . CONCLUSIONS: Coexisting @entity4 and @entity3 create unique health care needs by mutually activating and potentiating the other. There are very few comparable studies exploring the experiences of individuals when @entity1 and @entity3 coexist. The health care team can better develop treatment plans and test interventions sensitive to their unique needs when they understand the experiences of this population.

title: Health Care Experiences when XXXX and Substance Use Disorder Coexist: "Just Because I'm an Addict Doesn't Mean I Don't Have @entity1 ".

answer: @entity1


abstract: OBJECTIVE: To report the health care experiences of 34 individuals with coexisting @entity3 ( @entity3 ) and @entity4 . DESIGN: Narrative inquiry qualitative study of 90-minute interviews. SETTING: Midwest metropolitan @entity2 clinic. SUBJECTS: All individuals had @entity3 and were treated for @entity3 with @entity2 . They all self-identified as having @entity1 longer than 6 months. METHODS: This qualitative design allowed exploration of how @entity0 made sense of events related to living with @entity3 and @entity4 . Narrative inquiry gives a consistent story from the @entity0 ' perspective, and researchers can perform additional analysis using the storyline. Thematic analysis occurred of their health care experiences. RESULTS: Results revealed that @entity0 1) spoke about how they used deception to obtain opioids when their drug cravings were out of control; 2) were disturbed by health care providers having little understanding or ability to help them with their painful condition; 3) felt they wanted to abuse opioids again when receiving poor treatment by the health care team; 4) related what went well in their health care to help them maintain their sobriety; and 5) recommended improvements on health care interventions that included effective treatment of @entity1 . CONCLUSIONS: Coexisting @entity4 and @entity3 create unique health care needs by mutually activating and potentiating the other. There are very few comparable studies exploring the experiences of individuals when @entity1 and @entity3 coexist. The health care team can better develop treatment plans and test interventions sensitive to their unique needs when they understand the experiences of this population.

title: Health Care Experiences when @entity1 and Substance Use Disorder Coexist: "Just Because I'm an Addict Doesn't Mean I Don't Have XXXX ".

answer: @entity1